2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Saad Z. Usmani, MD, FACP, discusses future research directions with the combination of nirogacestat and teclistamab in patients with relapsed/refractory multiple myeloma.
Saad Z. Usmani, MD, FACP, chief of Plasma Cell Disorders and director of Clinical Research in Hematologic Malignancies, Levine Cancer Institute, Atrium Health, discusses future research directions with the combination of nirogacestat (PF-03084014) and teclistamab (JNJ-64007957) in patients with relapsed/refractory multiple myeloma.
Recently, SpringWorks Therapeutics announced it would be partnering with Janssen to open a phase 1 trial examining the combination of these agents. The most important objective of the trial is to evaluate the safety of the combination, Usmani says. Investigators estimate that the safety data from this trial will be generated and presented to the scientific community within 1 year, Usmani explains.
If the combination demonstrates positive safety and is shown to enhance clinical activity, it is likely that the next steps with this research would be to examine nirogacestat and teclistamab in combination with other therapies, Usmani concludes.